Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection by Gay, C.L. et al.
1Scientific RepoRtS |         (2020) 10:5134  | https://doi.org/10.1038/s41598-020-61878-3
www.nature.com/scientificreports
Assessing the impact of AGS-
004, a dendritic cell-based 
immunotherapy, and vorinostat on 
persistent HIV-1 Infection
Cynthia L. Gay1,2, Joann D. Kuruc1,2, Shane D. falcinelli  1,3, Joanna A. Warren1,3, 
Sarah A. Reifeis4, Jennifer L. Kirchherr1, Katherine S. James1, Morgan G. Dewey1, 
Alyson Helms1,2, Brigitte Allard1, Erin Stuelke1, Alicia Gamble7, Ana Plachco7, 
Robert J. Gorelick6, Joseph J. Eron1,2,5, Michael Hudgens4, Carolina Garrido1,2, 
Nilu Goonetilleke1,3, Mark A. DeBenedette7, Irina Y. Tcherepanova7, Charles A. nicolette7, 
Nancie M. Archin1,2 & David M. Margolis  1,2,3,5*
Approaches to deplete persistent HIV infection are needed. We investigated the combined 
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous dendritic cell 
immunotherapeutic, on the HIV reservoir. HIV+, stably treated participants in whom resting CD4+ t 
cell-associated HIV RNA (rca-RNA) increased after VOR exposure ex vivo and in vivo received 4 doses 
of AGS-004 every 3 weeks, followed by VOR every 72 hours for 30 days, and then the cycle repeated. 
Change in VOR-responsive host gene expression, HIV-specific T cell responses, low-level HIV viremia, 
rca-RNA, and the frequency of resting CD4+ T-cell infection (RCI) was measured at baseline and after 
each cycle. No serious treatment-related adverse events were observed among five participants. As 
predicted, VOR-responsive host genes responded uniformly to VOR dosing. Following cycles of AGS-
004 and VOR, rca-RNA decreased significantly in only two participants, with a significant decrease 
in SCA observed in one of these participants. However, unlike other cohorts dosed with AGS-004, no 
uniform increase in HIV-specific immune responses following vaccination was observed. Finally, no 
reproducible decline of RCI, defined as a decrease of >50%, was observed. AGS-004 and VOR were safe 
and well-tolerated, but no substantial impact on RCI was measured. In contrast to previous clinical data, 
AGS-004 did not induce HIV-specific immune responses greater than those measured at baseline. More 
efficacious antiviral immune interventions, perhaps paired with more effective latency reversal, must be 
developed to clear persistent HIV infection.
Life-long antiretroviral therapy (ART) is required to prevent rebound of viremia and return of disease, due to the 
persistence of long-lived viral reservoirs. Multiple mechanisms contribute to the complexity of latent and per-
sistent HIV infection1. One of the best studied drivers of HIV latency is epigenetic control of integrated proviral 
DNA2. Lysine acetylation of histone tails by histone acetyl transferases is believed to result the neutralization of 
basic charges of core histones, leading to destabilization of DNA/histone interactions, increased accessibility of 
transcription factors to the HIV promoter (LTR), and transcription initiation. Deacetylation of lysine residues 
on histone tails by histone deacetylases (HDACs) is associated with decreased access of positive transcription 
factors to the LTR, and recruitment of histone-modifying and chromatin complexes implicated in transcriptional 
repression. HDAC inhibition antagonizes repression of HIV transcription, and has been investigated as a tool to 
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reverse HIV latency in humans3–7. While administration of HDAC inhibitors (HDACi) in vivo increased HIV 
transcription in each of these studies, a corresponding depletion of persistent infection has not been observed. 
Reversal of HIV latency at the transcriptional level may not deplete persistent infection because a) the effect is 
insufficiently broad or too transient to impact the reservoir, and/or b) immune mechanisms are of insufficient fre-
quency or function to clear persistently infected cells following latency reversal, even in ART-treated individuals.
Exposure to the HDAC inhibitor vorinostat (VOR) induces HIV antigen expression sufficiently to allow 
viral clearance in vitro8,9. Four studies3,5–7 have demonstrated effective latency reversal in vivo at the level of 
cell-associated HIV RNA production following an initial dose of vorinostat (two studies), panobinostat, or 
romidepsin (one study each). Vorinostat has been shown to effectively and repeatedly reverse latency in vivo 
at the level of viral gene expression when given every 72 hours4. Therefore, we sought to determine whether 
the addition of an immunotherapy to the administration of a latency reversing agent (LRA) would clear reacti-
vated, formerly latently HIV-infected cells, leading to a decrease of the HIV reservoir. AGS-004 is a dendritic cell 
(DC)-based immunotherapy consisting of matured autologous DCs co-electroporated with in vitro transcribed 
ribonucleic acid (RNA) encoding autologous HIV antigens (gag, vpr, rev, and nef) plus synthetically derived clus-
ter of differentiation 40 ligand (CD40L) RNA to achieve DC functionality10. This vaccine was reported to induce 
HIV-specific effector/memory CD8 T-cell responses in HIV-infected individuals who had initiated ART during 
acute or chronic infection11–13.
In a prior open-label, single arm sub-study, AGS-004 was administered monthly to suppressed participants 
who started ART during acute HIV infection13. Participants demonstrating increased immune response after vac-
cination were eligible for analytic treatment interruption (ATI). The frequency of resting CD4+ T-cell infection 
(RCI) was measured by quantitative viral outgrowth assay. All participants underwent ATI with rebound viremia 
at a median of 29 days. AGS-00 before and after vaccination. induced a ≥2-fold increase from baseline in the 
number of multifunctional HIV-1 specific CD28+/CD45RA− CD8+ memory cytotoxic T-lymphocytes (CTLs) 
in all six participants, but did not permit sustained ART interruption. However, greater expansion of CD28−/
CCR7−/CD45RA− CD8+ effector T cell responses correlated with a longer time to viral rebound. In this study we 
investigated the impact of VOR combined with AGS-004, on persistent HIV infection.
Results
Clinical outcome of VOR/AGS-004 combination. Twelve ART-treated, stably aviremic participants 
were initially enrolled in this step-wise study. Informed consent was obtained from all patients prior to study 
enrollment. Baseline ART was maintained throughout the study. Given the theoretical risks of vorinostat, and the 
low likelihood of clinical benefit in this study, we first confirmed ex vivo exposure to VOR resulted in a measur-
able increase in rca-RNA in the resting CD4+ T cells of participants from a donation provided after screening. 
Participants who had a measurable response to VOR ex vivo as measured by a significant increase in rca-RNA in 
resting CD4+ T cells progressed to receive a single 400 mg oral dose of VOR. If a significant increase in rca-RNA 
was measured, then response following two paired in vivo doses of VOR given at a 72 hr interval was assayed, to 
confirm that a 72 hr dosing interval was reproducibly effective at inducing rca-RNA in vivo, as previously docu-
mented4. If a significant increase in rca-RNA was observed after the paired dose, then the participants went on to 
receive the combination of VOR and AGS-004.
Six of the 12 participants did not progress forward to receiving the single VOR dose either because of an 
absence of significant ex-vivo response to VOR (n = 5, data not shown) or withdrawal of consent due to personal 
circumstances unrelated to the study (n = 1). All 6 remaining participants received a single and then paired in 
vivo doses of VOR. We did not observe a significant increase in HIV RNA from the resting CD4+ T cells after 
administration of the in vivo paired VOR doses in one participant (VV-05), and thus per protocol this participant 
did not progress to receive further study treatments (data not shown).
Five participants, all male and white, received AGS-004 intradermal injections, and each dose consisted of 3 
injections. The study was closed to accrual thereafter, as manufacturer of the AGS-004 vaccine could no longer 
produce vaccine for the study. The median age was 50 years [range 29–62]. Viremia in all participants was sup-
pressed (<50 copies/ml) for at least 5.1 years [range 5.1–7.8] with a median baseline CD4+ count of 408 cells/µl 
[range 382–746] and median CD4 nadir of 166 cells/µl [range 81–403 l] at enrollment (Table 1).
Participants received 4 consecutive doses of AGS-004 administered every 3 weeks over 12 weeks. Seven to ten 
days following the last dose of AGS-004, participants initiated ten consecutive doses of VOR at 72 hr intervals. 
The cycle of 4 doses of AGS-004 followed by 10 doses of VOR was repeated within 10 weeks of completing the 
first cycle, for a total of eight AGS-004 doses and 20 doses of VOR over approximately 10 months (Fig. 1). Both 
AGS-004 and VOR were well tolerated by all participants with only mild AGS-004 site injection reactions, and 
possible VOR-associated mild, transient GI symptoms No symptoms approached grade I toxicity levels, and all 
resolved without treatment.
Expression of HDACi responsive genes confirm in vivo bioactivity of VOR. To confirm pharma-
cologic effect of VOR on cellular targets in vivo, we evaluated the expression of several genes with predictable 
behavior in response to HDAC inhibition in vitro. H1F0 and IRGM are upregulated and PHF15 and PRDM10 
are downregulated in bulk PBMCs as well as resting CD4+ T cells following exposure to HDACi14. Across the 5 
participants, we observed a pattern of gene modulation consistent with that described in ex vivo experiments 
and after a single in vivo VOR dose. H1F0 and IRGM were upregulated during q72 hour VOR dosing relative 
to baseline and returned to baseline levels after the cessation of dosing. Similarly, PHF15 and PRDM10 were 
downregulated during VOR dosing and returned to baseline expression levels after completion of dosing (Fig. 2). 
There were a few departures from this trend in some participants where certain genes were not modulated or 
modulated in the opposite direction from predicted (VV-01, PHF15; VV-02, H1F0 and IRGM); likely due to the 
multifactorial nature of transcriptional programming in vivo and variation associated with clinical sampling. 
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Overall, however, these data demonstrate that the pharmacological exposure to VOR in this study was sufficient 
to repeatedly alter host gene transcription over time.
Minimal impact on the latent HIV reservoir by VOR and AGS-004. It is hypothesized that therapies 
to disrupt virological latency, in combination with the use of vaccines or immunotherapies to assist in clearance 
of cells expressing HIV antigens, will be required to deplete the HIV reservoir. To that end we employed a dosing 
regimen of VOR that can repeatedly reverse latency in vivo4 together with an immunotherapeutic shown to gen-
erate HIV-specific immune responses10. We used several approaches to assess the impact of combined immuno-
therapy and latency disruption on the HIV reservoir. rca-RNA was measured at baseline, and after the first and 
second cycle of combined therapy. Low-level viremia was measured by a single-copy assay (SCA) at baseline, after 
the first series of AGS-004 administrations, after the first and second cycle of VOR and AGS-004, and 7–10 days 
after the last dose of VOR. Finally, we measured the frequency of resting CD4+ T-cell infection by the quantita-
tive viral outgrowth assay at the same time points as rca-RNA measurements. While the small sample size is a 
limitation of this study, we have previously identified a 6-fold decline in RCI measurement as a reliable threshold 
to assess the efficacy of anti-latency interventions in an individual, making it possible to capture a significant 
decrease in RCI even with a small sample size15.
We observed quantitative increases in HIV Gag rca-RNA after the first and second therapy cycle in two of 
five participants (VV-04 and VV-06), and after the second therapy cycle in a third participant (VV-03), which 
could be due to VOR induction in the absence of sufficient cell clearance, or simply assay variance. However, in 
VV-01 and VV-02 we observed increases in rca-RNA after the first therapy cycle but a significant decrease in HIV 
Gag rca-RNA following the second round AGS-004 and VOR administration (Fig. 3). We observed a significant 
decrease in low-level viremia as measured by SCA (Table S1) for VV-02 (4.3 copies/ml at entry, and less than 0.5 
copies/ml in three assays between visit 14 and 25), but viremia in other participants was either <1.0 or 1.1 copies/
ml at all timepoints (VV-01, VV-03, VV-04), or intermittently detected from <1.0 to 84 copies/ml without a clear 
pattern (VV-06). However, the observed changes in rca-RNA and low-level viremia was not associated with a cor-
responding depletion of the replication competent reservoir as we failed to observe a significant decrease in RCI 
in all the participants (Table S2). Not unexpectedly, HIV DNA with resting CD4+ T cells was also stable (Fig. S1).
Ex-vivo T cell immune reactivity to AGS-004. T cell responses to HIV proteins were measured longitu-
dinally by ex vivo IFN-γ ELISpot in each participant at time points before and after VOR and AGS-004 dosing. 
T cell responses were measured against both, proteins within the AGS-004 vaccine (Gag, Nef-Rev-Vpr), and 
others not in the vaccine (Env, Pol, Tat-Vif-Vpu). In VV-01, VV-02, VV-04, and VV-05, T cell responses to all 
HIV proteins, both those included or not included in the vaccine, were stable across time points. Less than a 
1.5-fold change was observed from baseline in the frequency of HIV-specific T cell responses, whether total, or 
targeting proteins within or outside of the vaccine’s immunogens (Fig. S2). In VV-03, the summed HIV-specific 
T cell response increased ~1.5 fold over the course of the study. After the first cycle of AGS-004 dosing, summed 
HIV-specific T cell response increased from 1,434 SFU/106cells at visit 2 to 2,121 SFU/106cells at visit 16. The 
summed HIV-specific T cell response again increased after cycle 2 from 1,390 SFU/106cells at visit 20 to 2,250 
SFU/106cells at visit 25. Importantly, the increases to the summed HIV-specific T cell response were driven by 
increases in T cells targeting HIV proteins found in the vaccine (Gag, Nef/Rev/Vpr subpool, 1093 SFU/106cells at 
visit 2 to 1,751 SFU/106cells at visit 16, and 1,105 SFU/106cells at visit 20 to 1,951 SFU/106cells at visit 25), and not 
to proteins outside of AGS-004 (Pol, Env, Tat/Vif/Vpu subpool, 341 SFU/106cells at visit 2 to 370 SFU/106cells at 
visit 16, and 284 SFU/106cells at visit 20 to 299 SFU/106cells at visit 25), suggesting the increases observed, while 
modest, were vaccine-induced (Fig. S2). In summary, as previously reported4, VOR dosing had no effect on the 
HIV-specific T cell response. The AGS-004 vaccine induced T cell responses in ex vivo ELISpot in only 1 of 5 
participants.
Assessment of T cell and NK immune reactivity to AGS-004. Previously, we reported in both acute 
and chronically infected HIV participants on ART therapy, an increase in the CD28+/CD45RA− CD8+ memory 
CTL response after AGS-004 administration10,13. Therefore, we assessed immune response in this way for partici-
pants receiving cycles of AGS-004 followed by VOR (Fig. 1). Baseline immune response was measured following 
VOR prior to AGS-004 dosing. Subsequent immune responses were measured at multiple timepoints during 
AGS-004 and VOR dosing, and at protocol completion.
Numbers of CD28+/CD45RA− CD8+ memory CTL determined after in vitro stimulation with autologous 










Status at ART 
Initiation*
VV-01 Caucasian 49.6 542 403 8 FTC, EFV, TDF AHI
VV-02 Caucasian 54.4 682 81 6.9 RTV, TDF, FTC, NVP, fAPV CHI
VV-03 Caucasian 30.2 382 354 5.8 TDF, FTC, ETR CHI
VV-04 Caucasian 54.3 408 157 6.1 EVG, COBI, FTC, TDF CHI
VV-06 Caucasian 28.4 701 166 4.9 DRV, RTV, TDF, FTC CHI
Median — 49.6 542 166 6.1 — —
Table 1. Participant characteristics. *AHI: acute HIV Infection; CHI: chronic HIV infection. **At baseline. 
ΨPre-Art.
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numbers of CD28+/CD45RA− CD8+ memory CTL could be detected at various timepoints after the first or 
second cycle of AGS-004 and/or during VOR treatment, only participants VV-02 and VV-03 had significantly 
increased numbers of CD28+/CD45RA− CD8+ memory CTL which met the criteria for a positive immune 
response at visit 23. For participant VV-02 a positive response was recorded during both the first and second 
cycles of combined therapy. For VV-03 a positive response was recorded only during the second cycle of com-
bined therapy. Individual functional marker responses within the total CD28+/CD45RA− CD8+ memory CTL 
immune response for each subject are shown (Fig. S3).
To further understand an AGS-004-induced immune response, we measured the total numbers of CD8+ T 
cells with any functional response at baseline and after each cycle of combined therapy, where sufficient cells were 
available for analysis (VV01-VV04). This analysis was undertaken to gauge the overall functional CD8+ T cells 
Figure 1. AGS-004–009 Study Design. A) Overall study design. Resting CD4+ T cell-associated HIV gag 
RNA was measured at baseline, after the single dose, the paired dose and the first and second cycle of VOR 
plus AGS-004. RCI was measured at baseline, and after the first and second cycle of VOR+ AGS-004. X details 
immune monitoring (IM) sample collection to determine immune responses by multi-color flow cytometry. X 
denotes the timepoints of blood draw collection. The purple X (Visit 10) represents the time point before the 
administration of AGS-004 and serves as the baseline prior to immunological measurements (unless otherwise 
noted in a given figure).
Figure 2. Vorinostat dosing resulted in induction of HDACi-responsive host genes in PBMCs. PBMCs were 
collected immediately prior to the 1st VOR dose, after the 5th and 10th q72h dose, and 7–10 days after the 10th 
dose during cycle I and II. Expression of HDACi-responsive host genes was assessed relative to the pre-dose 
time point for each cycle. Error bars represent standard deviation of the mean of triplicate cDNA preparations, 
each conducted in duplicate qPCR reactions.
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response after ex vivo stimulation with autologous DCs. Overall there were statistically significant increases in 
CD8+ T-cells expressing granzyme B (Grb) in vitro for these participants (Fig. 5). The responses for participants 
VV-02 and VV-03 also became more multi-functional after cycle I and cycle II of combination therapy respec-
tively with statistically significant increases in the numbers of CD8+ T cells secreting cytokines in combination 
with Grb.
Recent observations have reported that the in vivo administration of histone deacetylase inhibitors do not 
impair natural killer cell function in HIV+ individuals16. Therefore, we also measured NK cell responses after a 
six-day PBMC co-culture with or without autologous DCs. NK cells were defined using the CD3−CD56+CD16+ 
phenotype, with negative expression for both CXCR4 and CD45RA. After co-culture, activated NK cells (defined 
by expression of Grb) were present in all participants, and the percentage of activated NK cells increased follow-
ing the first and second cycles of VOR in participants VV-02 and VV-03. When autologous DCs were added to 
co-cultures, the percentage of activated NK cells was also increased for participants VV-01 and VV-02 (Fig. 6). 
There was no significant increase in the percentage of activated NK cells determined for subject VV-04.
Viral Inhibition Assays. We have previously demonstrated the potential of various immunotherapies to 
augment HIV-specific effector responses, as measured by an in vitro autologous viral inhibition assay (VIA)17,18. 
Figure 3. The effect of AGS-004 and VOR on HIV gag ca-RNA expression. Cell-associated HIV RNA was 
measured from pools of 24–36 million resting CD4+ T cells isolated from participants at baseline and after the 
first and second cycle of VOR+ AGS-004. Wilcoxon Two-Sample Test was used to assess significant differences 
in HIV Gag caRNA between baseline and cycle I (A) and baseline and Cycle II (B) samples. Mean and SD is 
shown with corresponding p values. ‡Indicates a decrease in caRNA following cycle II of AGS-004 +VOR with 
corresponding p values.
Figure 4. Immune response after in vitro stimulation with autologous DCs. Number of CD28+/CD45RA− 
CD8+ memory CTLs proliferating (BrdU positive) or expressing CD107a, GrB, IFN-γ, IL-2, or TNF-α were 
determined at the indicated time points during cycles of combination therapy. The numbers of cells/mL were 
determined by adding the numbers of cells/mL measured for each individual functional marker. Values were 
derived from the average and standard deviation of triplicate cultures.
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To explore the possible correlations between in vivo responses in this pilot trial and the VIA, we assessed the 
antiviral activity of CD8+ T cells obtained after VOR and AGS-004 administration towards autologous partici-
pant CD4+ T cells super-infected with the laboratory strain JR-CSF or with HIV recovered and amplified from 
the individual’s resting CD4+ T cells (autologous reservoir virus, ARV). CD8 T cells from all participants except 
VV-01 and VV-04 had little antiviral activity at baseline in this assay. We observed a trend towards an increase in 
the anti-viral capacity of CD8 T cells post VOR and AGS-004 treatment for VV-02 against JRCSF, and for VV-01 
and VV-04 against both JRCSF and autologous reservoir virus (Figs. 7 and S4). However overall, no significant 
statistical differences were found between the antiviral activity of CD8+ T cells isolated before and after treatment 
for all participants.
Discussion
Currently antiretroviral therapy does not eliminate HIV-1 from latently-infected reservoirs19–21, and this remains 
the critical limitation to HIV eradication. Given a rapidly expanding number of HIV-infected individuals on life-
long ART worldwide, there is an urgent need for innovative therapies to control HIV-1 infection beyond what is 
currently possible with ART. We present the results of a pilot study combining a validated latency reversing agent 
with an immunotherapeutic shown to generate HIV-specific immune responses13.
Resting CD4+ lymphocytes comprise the largest and best characterized reservoir of HIV infection that persists 
despite ART22. Host cell molecular mechanisms that maintain the quiescence of HIV gene expression in infected 
resting CD4+ lymphocytes provide therapeutic targets within this largest and best-defined reservoir of HIV 
infection that persists despite ART. One of these latency mechanisms is the recruitment of histone deacetylases 
(HDACs) to the HIV long terminal repeat (LTR) promoter, mediating the formation of a repressive chromatin 
environment, a well-defined mechanism that inhibits LTR expression and HIV viral production. The relevance of 
this mechanism has been validated in numerous model systems and in the resting CD4+ T cells of ART-treated, 
aviremic individuals living with HIV2.
We and others have shown that HDAC inhibitors, such as VOR, can reverse HIV latency as measured by sig-
nificant increase in cell-associated RNA expression3,5–7. In this study we administered VOR every 72 hours, as we 
had established this interval could repeatedly induce rca-RNA expression without significant clinical toxicity or 
immune dysfunction4,23,24.
In addition to latency-reversing agents, an enhanced and persistent HIV-1 specific immune response will be 
a required component of any cure strategy. Accordingly, this pilot study combined VOR administration with an 
HIV-1 specific immune therapy demonstrated activity in HIV-1 infected participants. The AGS-004 DC therapy 
is an individualized immunogen, and as generated from autologous PBMCs, addresses the inherent problem of 
HIV genetic diversity when using consensus HIV protein sequences as immunogens.
In a prior study, AGS-004 was safe and immunogenic in participants who initiated ART during acute HIV 
infection (AHI)11. DC therapy was administered to participants who initiated ART within 45 days of AHI and 
had HIV RNA < 50 c/ml for >6 months. Participants received 4 monthly doses of AGS-004 on ART. All six 
Figure 5. Total CD8+ T-cell functional immune responses after in vitro stimulation with autologous DCs. 
Functional CD8+ T-cells defined as proliferating (BrdU positive) or expressing CD107a, GrB, IFN-γ, IL-2, or 
TNF-α were determined at baseline and after cycle I and cycle II of combination therapy. Cycle I corresponds 
to Visit 16 and Cycle II to Visit 25. Only functional markers for which positive responses above baseline were 
observed are displayed in each chart legend. Values were derived from the average and standard deviation of 
triplicate cultures. Starred markers (*) indicate an increase in the numbers of functional CD8+ T-cell responses 
above baseline with p < 0.05; NS: p > 0.05.
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participants demonstrated positive immune responses defined as ≥2-fold increase from baseline in the number 
of CD28+/CD45RA− CD8+ memory CTL that display effector function to the antigens contained in AGS-004, 
Vpr, Nef, Gag, and Rev. These responses were durable over 12 weeks.
Other DC-based HIV vaccines have been developed and undergone clinical testing, these include autologous 
DCs transfected with gag/nef mRNA25, DCs loaded with autologous HIV infected apoptotic cells26, DCs pulsed 
with heat-inactivated whole HIV27, and DCs loaded with HIV lipopeptides28. In most of these clinical trials a 
slight improvement in HIV specific T cell responses was observed in terms of activation, breadth and frequency 
of functional T cells. Unfortunately, virologic outcomes were limited upon treatment interruption, with only 
modest decreases in the viral load set point. However, a correlation between immune function enhancement and 
viral load reduction was observed. Finally, because of the large inter-individual variation observed in the vaccine 
response, it has been proposed that factors such as the host genetics might play an important role in immuno-
therapy outcomes29,30.
This pilot study in HIV-1-positive participants with durable viral suppression on stable ART sought to meas-
ure the potential of AGS-004 combined with Vorinostat to (1) stimulate expression of persistent proviral HIV 
from resting CD4+ T cells, (2) generate an HIV-specific immune response, and (3) when combined, clear persis-
tent infection in HIV-infected participants in whom viral replication and spread is inhibited by uninterrupted 
ART.
12 participants enrolled in the study. One participant withdrew for personal reasons (relocation). Five were 
not advanced into the treatment steps of the protocol as no significant HIV RNA induction could be measured, 
most often due to low levels of RNA detected prior to cell treatment (<35 copies HIV RNA/million resting CD4 
T cells). In only one participant, significant HIV RNA induction was measured ex vivo, but was not observed after 
a single oral dose of VOR, and so the participant did not advance to further treatment. In all five participants, ex 
vivo induction of HIV RNA expression was paralleled by induction following both a single dose of VOR, and by 
the second of two doses of VOR separated by 72 hours. Following this observation, in our other ongoing studies 
we now screen only for in vivo response using paired dosing.
Overall, we found the combination of AGS-004 DC therapy and VOR to be safe and well-tolerated. No 
study-treatment related adverse events greater than Grade I were observed. The most common Grade I events 
were mild, self-resolving injection site reactions related to AGS-004.
Assays to assess histone acetylation as an in vivo biomarker of VOR pharmacologic activity are 
time-consuming and qualitative. We employed a PCR-based assay described by Maxwell et al. (manuscript sub-
mitted) to assess the impact of VOR on host gene transcription, as a measure of host target engagement. The two 
host genes up-regulated (H1F0, IRGM) and two host genes that are down-regulated (PHF15 and PRDM10) were 
modulated as predicted upon repeated VOR dosing, suggesting that this assay will be useful in future clinical 
studies of HDAC inhibitors.
Figure 6. Determination of activated NK cells in PBMC co-cultures stimulated with autologous DCs. PBMCs 
at baseline, after cycle I, and after cycle II were cultured with or without autologous DCs for 6 days. Activated 
NK cells were identified as CD3-/CXCR4-/CD45RA- cells expressing CD15, CD16, and GrB. Percentages of 
activated NK cells were determined from the average of triplicate cultures. †Indicates p < 0.05 between no 
DC stimulation (filled bars) or with DC stimulation (open bars). *Indicates p < 0.05 cultures between no DC 
stimulation or with DC stimulation. NS: p > 0.05.
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Unfortunately, these interventions had no measurable impact on the replication competent reservoir as meas-
ured by QVOA. We observed a significant decline of rca-RNA in two of 5 participants after the second cycle of 
combination therapy. This could reflect depletion of cells producing full-length HIV RNA, a substantial pro-
portion of which might not have been replication-competent31 and might therefore not contribute to a decline 
of RCI. As the frequency of cells expressing HIV RNA is much larger than that of cells capable of producing 
replication-competent HIV32, a significant but modest decline of rca-RNA may not be measurable as a significant 
decline of RCI. Alternatively, this decline could have been driven by another unknown cause of assay variation, 
as the rca-RNA assay has not been extensively characterized in longitudinal studies33. Given the small sample 
size and lack of a control group, we cannot completely dismissed that some of the increase or decrease in caRNA 
is perhaps due to longitudinal variation in cRNA expression34. However, of note, VV-02 also had a decline in 
single-copy assay plasma viremia (SCA) from 4 copies/µl to <1.0 copies µl at all post-AGS-004 timepoints, but 
SCA levels were too low to assess in 3 other participants and were unaffected in a fourth (VV-06).
There are several limitations to this work including as mentioned earlier, the small sample size and lack of 
a control group for this pilot study. Further, it is possible that more of an effect would have been seen with this 
combined immunotherapeutic strategy in participants who initiated ART earlier during acute infection or with 
higher baseline CD4 counts; three of five participants in this study had a CD4 nadir <200. However, one partic-
ipant (VV-01) who started ART during acute infection did not demonstrate an increased response compared to 
those starting ART during established HIV infection.
Another factor that should be taken into consideration is that while we have evidence from an ex-vivo model 
system that VOR can induce sufficient antigen in resting CD4+ T cells from ART-treated participants to allow 
clearance of HIV infected cells by autologous CD8 T cells9, this finding has not yet been validated in vivo. 
Furthermore, while we can infer that there is sustained antigen presentation by AGS-004 DCs based on prolonged 
IL-12 secretion as a result of the CD40L RNA co-electroporated along with the HIV RNA, we cannot completely 
dismiss the possibility that suboptimal HIV antigen presentation by DCs in vivo contribute to the limited success 
of this study. Indeed, these questions can only be fully addressed in an in vivo study such as this one.
In this limited pilot study, absent clear findings in primary virological endpoints, we sought to probe for 
correlations between immune effects and the limited virological effects seen in VV-01 and VV-02. However, 
augmentation of the several immune responses measured were not consistently seen in these two participants. 
In summary, the serial administration of VOR appeared to reverse HIV latency in this selected cohort without 
Figure 7. Viral inhibition assays using isolated CD8+ T cells from each of the participants before and after the 
clinical treatment. CD8 depleted PBMCs were stimulated with PHA and infected with either the viral strain 
JRCSF or autologous reservoir virus (AutoRV) and CD8+ T cells were added at an E:T ratio of 1:1 or 1:10. Viral 
replication was assessed by measuring HIV gag p24 in the supernatant after 6 days of culture. Results were 
normalized for each participant to the targets alone condition (100%). No significant statistical differences were 
found between the antiviral activity of CD8+ T cells isolated before and after treatment.
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clinical toxicity. However, no substantial augmentation of anti-HIV immune function was uniformly seen in this 
cohort of durably treated individuals living with HIV. Surprisingly, the induction and magnitude of HIV-specific 
immune responses by AGS-004 was marginal and inconsistent across participants, in contrast to what has been 
reported for AGS-004 elsewhere13. The combination of AGS-004 DC therapy and VOR resulted in a decrease 
in cell-associated HIV RNA only in a minority of participants and had no substantial or uniform impact on 
the replication competent reservoir. Interestingly, depletion of the reservoir was not substantial even in the two 
participants with a measurable decrease in HIV rca-RNA, consistent with prior findings that most rca-RNA is 
replication defective. The need for the development of more potent latency reversal agents that robustly target 
the replication competent reservoir together with more efficacious immune interventions remains an important 
priority towards achieving an HIV cure.
Materials and Methods
Human subjects. This study was reviewed and approved by the University of North Carolina biomed-
ical institutional review board, the NIAID Clinical Sciences Review Committee, and the Food and Drug 
Administration. This study, NCT02707900, was registered at Clinicaltrials.gov on 14 March 2016 and clinical 
trial monitoring performed by the NIAID. All research was performed in accordance with relevant US and insti-
tutional guidelines and regulations, and informed consent was obtained from all participants.
Measurements of HDAC responsive genes. PBMC were collected immediately prior to the first VOR 
dose, 4 hours after the 5th and 10th VOR dose, and 7–10 days after cessation of dosing. RNA was extracted using 
the Qiagen RNeasy kit (Germantown, MD), and was quantified using the NanoDrop1000 (Thermo Fischer 
Scientific, Waltham MA). Three reactions of cDNA per sample, each with an RNA input of 500 ng, were pre-
pared using the Maxima cDNA synthesis kit with dsDNase according to the manufacturer’s instructions (Thermo 
Fischer Scientific).
cDNA reactions were diluted 1:4 and subsequently used for qPCR in technical duplicates. 20 uL qPCR reac-
tions consisted of 10 uL of QuantiTect Multiplex PCR NoROX Mastermix (Qiagen), 0.25 uL of AmpErase™ 
Uracil N-Glycosylase (Thermo Fischer Scientific), 2 uL of diluted cDNA, 400 nM or 1X primers, and 200 nM or 
1X probes. Primers/probe sets for assessment of HDACi-modulated gene expression included previously val-
idated primer/probe sets for H1F0, IRGM, and RPL27 from Integrated DNA Technologies14 or pre-designed 
20X Taqman assays for PHF15 (Hs00959516) and PRDM10 (Hs00999748) from Thermo Fisher Scientific. qPCR 
cycling was conducted on the Bio-Rad C1000 Touch Thermal Cycler as follows: 50 °C × 2 min, 95 °C × 15 min, 
followed by 40 cycles of 94 °C × 1 min and 64 °C × 1 min. Cq values were determined using the automatic thresh-
old analysis in the Bio-Rad CFX Maestro Software Version 1.1. Expression of HDACi-modulated host genes was 
assessed using the 2−∆∆Ct method35. RPL27, a gene known to be non-responsive to HDACi stimulation, was used 
a reference gene36. For each round of vorinostat dosing in the study, fold change values were calculated relative to 
the baseline sample acquired immediately prior to dosing.
Quantitative viral outgrowth assay (QVOA). Lymphocytes were obtained by continuous-flow leu-
kopheresis. Isolation of resting CD4+ T cells, recovery and quantification of replication competent virus was per-
formed as described previously3,37. Briefly, approximately 50 million resting CD4+ T cells were plated in replicate 
limiting dilutions of 2.5 million (18 cultures), 0.5 million (6 cultures) and 0.1 million (6 cultures) cells per well, 
activated with PHA (Remel, Lenexa, KS) and a 5-fold excess of allogeneic irradiated PBMCs from a seronega-
tive donor, and 60 U/ml IL-2 for 24 hours. Cultures were washed and co-cultivated with CD8-depleted PBMCs 
collected from selected HIV seronegative donors screened for adequate CCR5 expression. Culture supernatants 
were harvested on days 15 and 19 and assayed for virus production by p24 antigen capture ELISA (ABL, Rockville 
MD). Cultures were scored as positive if p24 was detected at day 15 and was increased in concentration at day 19. 
The number of resting CD4+T cells in infected units per million (IUPM) was estimated by a maximum likelihood 
method3,38,39.
Measurement of cell-associated HIV DNA, RNA and low-level viremia. DNA was extracted 
from participant resting CD4 T cells using the Qiagen DNeasy® Blood & Tissue kit (Qiagen). Four replicates 
of 1 microgram of DNA was added to ddPCR™ Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA) with 
HindIII restriction enzyme for DNA digestion. Total HIV DNA was assessed using previously published primers 
and probe40 and standard ddPCR thermocycling conditions (Bio-Rad). Cell normalization was performed using 
two replicates of RPP30. Wells were merged together using the Bio-Rad Quantasoft Software and normalized to 
copies/million.
Changes induced in rca-RNA in vivo in response to VOR and AGS-004 dosing was measured as previously 
described with some minor modifications3. Immediately following leukapheresis, resting CD4+ T-cells were iso-
lated and plated at 1 million cells/well, pelleted, snap frozen, and stored at −80 °C. Total RNA was isolated from 
36 replicates of 1 million resting cells using the Magmax 96 Total RNA isolation kit (Life Technologies, Carlsbad, 
CA) following the manufacturer’s protocol. cDNA was synthesized in duplicate from DNase-treated, isolated 
RNA using the SuperScript® III First-Strand Synthesis SuperMix kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s procedures. Reverse transcriptase was omitted from duplicate wells of each treatment condition 
and those wells served as controls for DNA contamination. Duplicate PCR amplification of duplicate cDNA was 
performed using the Biorad FX96 Real-Time PCR machine and previously published primers and probe41. A 
standard curve was generated for each PCR reaction as described previously3. Results of the four PCR replicates 
representing each of the original 36 pools of RNA were averaged and the standard deviation determined for each 
condition. Statistical significance was determined as described under the statistical analysis subheading.
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To measure low level viremia, HIV-1 from plasma was isolated by ultracentrifugation, the resulting pellet was 
extracted as described in Cline et al.42. HIV gag RNA copy numbers were assessed using the qPCR assay described 
in Somsouk et al.43. HIV-1 viral loads are reported as copies/mL of plasma.
AGS-004 Manufacturing and dosing. AGS-004 was manufactured at Argos Therapeutics, (Durham, NC) 
as previously described10. Monocytes were isolated from the leukocytes by elutriation and cultured in AIM-V 
media with 800 U/mL GM-CSF (Berlex Laboratories, Wayne NJ) and 1000 U/mL IL-4 (R&D Systems, Minneapolis 
MN) to generate immature DCs that are matured using 20 ng/mL TNF-α) (R&D Systems)/1000 U/mL 
IFN-γ (InterMune, Brisbane CA)/1 μg/mL PGE2 (Sigma, St. Louis MO). Mature DCs were electroporated with 
autologous pre-ART HIV RNA encoding Gag, Nef, Vpr and Rev and CD40L RNA using a post-maturation elec-
troporation protocol described previously10. The final AGS-004 product was formulated as 1.4 × 107 DC/0.7 mL 
in 80% autologous plasma, 10% dextrose (50% w/v) (Hospira Lake Forest IL), and 10% DMSO (Sigma) and cryo-
preserved in liquid nitrogen vapor phase. Each patient was treated with an autologous dose of AGS-004 supplied 
as a cryopreserved, single dose vial containing a minimum of 6 million autologous matured dendritic cells (target 
1.2 × 107 DCs) in 0.7 mL of suspension and is administered into a single lymph node basin as three intradermal 
injections of 0.2 mL each (0.6 mL total volume)10.
Elispot assays. 18-mer peptides overlapping by 10 amino acids were synthesized (Sigma-Genosys) to match 
the HIV Clade B consensus sequence and pooled by proteins in the AGS-004 vaccines Gag and Nef-Rev-Vpr and 
proteins not included in the vaccines, Pol, Env, Tat-Vif-Vpu. Peptide pools (quadruplicate) were pre-aliquotted 
into 96-well RB plates with media-only negative (6 replicates) and PHA positive control (duplicate) wells then 
stored at −80 °C. Cryopreserved PBMCs were thawed and rested O/N before being added to ELISpot plates 
(Merck, Millipore) at 4 × 105 cells per well. All timepoints for each participant were run together. Antigens in the 
thawed peptide plates were mixed with 1:1 with PBMCs in the ELISpot plate to a final concentration of 2 μg/ml 
and incubated for 18–20 hours at 37 °C, 5% CO2. Coating, development (MabTech), and reading of ELISpot 
plates (AID Reader) has been described previously44. Positive T cell responses were defined as ≥12.5 SFU per 
million, >4 times the average of replicate background wells. Zero values were not accepted in any replicate of 
antigen-stimulated wells.
Flow cytometry analysis of immune response. To determine immune responses by multi-color flow 
cytometry, PBMCs collected at the indicated timepoints (Fig. 1) for 4 of the 5 participants were cultured in vitro 
with autologous DCs product obtained from the manufacturing runs to measure HIV-specific T cell responses 
in vitro to the combination RNA antigen payload (GNVR) as described previously10,45. An insufficient amount of 
PBMC were obtained from participant VV-06 for this analysis.
Briefly, PBMCs were processed by Ficoll density gradient separation from whole blood draws and stored fro-
zen. When all blood draws were collected from a participant, PBMCs were thawed and rested overnight in X-Vivo 
15 supplemented with 10% Human AB serum. After overnight rest PBMCs were labeled with bromodeoxyuridine 
(BrdU) to track T-Cell proliferation and cultured with autologous DC targets and incubated at 37 °C for 6 days. 
On day 6, cultures were re-stimulated with autologous DCs and anti-CD107a antibody was added to each tube 
and incubated at 37 °C for 5 hours in the presence of Brefeldin A (BD Biosciences, Franklin Lakes NJ). After incu-
bation, cells were stained for viability using a viability dye (Invitrogen, Carlsbad CA) followed by surface staining 
with specific antibodies for detection of CD28, CD45RA, CD3, and CD8 expression. After surface staining, cells 
were fixed with 4% BD Cytofix and stored overnight in BSA staining buffer at 4 °C. The following day, the cells 
were permeabilized and DNase treated for 1 hour at 37 °C using reagents included in the BrdU staining kit (BD 
Biosciences). Intracellular staining for IFN-γ, TNF-α, IL-2, Grb and BrdU were performed. After staining, cells 
were washed and diluted in 500 µl BSA buffer and transferred to a BD TruCount Tube (BD Biosciences) for 
acquisition on a BD LSRII cytometer. 400,000–600,000 events were collected per sample. Number of cells/ml was 
calculated using the following formula; (number of cellular events collected/number of beads collected) × (bead 
concentration)/collected volume) × 100045.
The absolute number of viable CD8+ CD3+ T-cells positive for CD28 and negative for CD45RA and express-
ing any of the following six functional markers, IFN-γ, TNF-α, IL-2, GrB, CD107a, or the expression of the 
proliferation marker, BrdU were identified to the total HIV antigen payload. To determine the total number of 
functional CD28+/CD45RA− CD8+ memory CTLs, the numbers of CD28+/CD45RA− CD8+ memory CTLs hav-
ing any functional activity were added together to determine absolute cells/mL. Per protocol, a positive immune 
response to AGS-004 was defined as >2-fold increase (plus 3 times STD) over baseline in the absolute number of 
CD28+/CD45RA− CD8+ memory CTLs (cells/mL) exhibiting at least one effector function defined by the expres-
sion of IFN-γ, TNF-α, IL-2, GrB, CD107a, or proliferation. Baseline was defined as Visit 10 to designate the time 
prior to administration of AGS-004.
For detection of NK cells, frozen PBMCs were thawed and rested overnight and then cultured for 6 days with 
or without autologous DCs. After 6 days of culture cells were surface stained with antibodies to the following 
markers: CD3, CD4, CD8, CD25, CD45RA, CD16, CD56, and CxCR4 followed by staining for viability using 
Aqua Live/Dead Fixable Dye. Cells were washed and Transcription Factor Buffer set (BD Biosciences) was used 
to fix the cells. Following overnight storage at 4 °C in FBS stain buffer, cells were permeabilized by washing in 
Perm Wash buffer. Human IgG FC block was added to prevent non-specific antibody binding. After washing 
intracellular antibody to Grb was added. Cells were washed and acquired in BD True Count tubes for acquisition 
on a BD LSRII cytometer using FACSDiva software and 400,000–600,000 events were collected per sample. Data 
from acquired samples were analyzed using Flowjo software versions 9.7.6 (Ashland OR). Insufficient PBMC were 
collected from participant VV-04 at visit 25 for analysis so visit 23 was used for an analysis after cycle II.
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Viral inhibition assay. Viral inhibition assay was performed as previously described17. CD8+ T-cells were 
isolated from PBMCs by positive selection (EasySep human CD8+ Selection Kit, Stem Cell, Vancouver, BC). 
CD8-depleted PBMCs were first activated with 4 μg/mL of PHA (Remel, Lenexa, KS) and 60 U/mL of IL-2, and 
then infected by inoculation at 1200 × g for 90 minutes with either JR-CSF or autologous reservoir virus (AR) at 
a MOI of 0.01. AR virus was obtained from pooled supernatants of replicate wells from outgrowth assays of rest-
ing CD4+ T-cells from each patient. Fifty-thousand (5 × 104) targets/well were co-cultured with CD8+ T cells in 
triplicate at the indicated effector to target (E:T) ratio in 0.2 m of cIMDM media supplemented with 10% FBS, 1% 
Penicillin/Streptomycin and 5 U/mL IL-2. P24 concentration in supernatant was assayed on day 6 by p24 ELISA 
(ABL, Rockville, MD).
Statistical analysis. The Wilcoxon Two-Sample test was used for statistical analysis of rca-RNA of pre- and 
post-VOR+ AGS-004 exposure groups. For viral inhibition assays, the Wilcoxon-Signed Rank test was used for 
statistical assessment of the effect of AGS-004 on the anti-viral function of CD8+ T cells.
CD28+/CD45RA− CD8+ memory CTL responses at baseline and after AGS-004 administration were com-
pared statistically using a 2-tailed Student t-TEST. Positive responses were determined by subtracting two times 
the total number of functional CD28+/CD45RA− CD8+ memory CTLs at baseline, from the total number of 
functional CD28+/CD45RA− CD8+ memory CTLs measured in response to in vitro stimulation with DC encod-
ing the HIV antigens. Finally, the percentage of activated NK cells at baseline and after AGS-004 administration 
were compared statistically using a 2-tailed Student t test.
Data availability
All data is available in the main text or the supplementary materials.
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